Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)

Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Hepatitis B Treatment Market: Product Outlook

5. Global Hepatitis B Treatment Market: Growth and Forecast
5.1. Global Hepatitis B Treatment Market, By Value (2012-2016)
5.2. Global Hepatitis B Treatment Market, By Value (2017-2022)
5.3. Global Hepatitis B Treatment Market - By Type, By Value
5.3.1. Global Hepatitis B Treatment Market, By Value, % (2016)
5.3.2. Global Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
5.4. Global Hepatitis B Treatment Market, By Type, By Value (2012-2022)
5.4.1. Therapeutics, By Value (2012-2022)
5.4.2. Vaccines, By Value (2012-2022)
5.5. Global Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
5.5.1. Male, By Value (2012-2022)
5.5.2. Female, By Value (2012-2022)

6. North America Hepatitis B Treatment Market: Growth and Forecast
6.1. North America Hepatitis B Treatment Market, By Value (2012-2016)
6.2. North America Hepatitis B Treatment Market, By Value (2017-2022)
6.3. North America Hepatitis B Treatment Market - By Type, By Value
6.3.1. North America Hepatitis B Treatment Market, By Value, % (2016)
6.3.2. North America Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
6.4. North America Hepatitis B Treatment Market, By Type, By Value (2012-2022)
6.4.1. Therapeutics, By Value (2012-2022)
6.4.2. Vaccines, By Value (2012-2022)
6.5. North America Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
6.5.1. Male, By Value (2012-2022)
6.5.2. Female, By Value (2012-2022)

6.6. North America Hepatitis B Treatment Market: Country Analysis (U.S., Canada)
6.6.1. North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
6.6.2. North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)

6.7. U.S. Hepatitis B Treatment Market: Growth and Forecast
6.7.1. U.S. Hepatitis B Treatment Market, By Value (2012-2016)
6.7.2. U.S. Hepatitis B Treatment Market, By Value (2017-2022)
6.8. U.S. Hepatitis B Treatment Market - By Type, By Value
6.8.1. Therapeutics, By Value (2012-2022)
6.8.2. Vaccines, By Value (2012-2022)
6.9. U.S. Hepatitis B Treatment Market - By End-User, By Value
6.9.1. Male, By Value (2012-2022)
6.9.2. Female, By Value (2012-2022)

6.10. Canada Hepatitis B Treatment Market: Growth and Forecast
6.10.1. Canada Hepatitis B Treatment Market, By Value (2012-2016)
6.10.2. Canada Hepatitis B Treatment Market, By Value (2017-2022)
6.11. Canada Hepatitis B Treatment Market - By Type, By Value
6.11.1. Therapeutics, By Value (2012-2022)
6.11.2. Vaccines, By Value (2012-2022)
6.12. Canada Hepatitis B Treatment Market - By End-User, By Value
6.12.1. Male, By Value (2012-2022)
6.12.2. Female, By Value (2012-2022)

7. Europe Hepatitis B Treatment Market: Growth and Forecast
7.1. Europe Hepatitis B Treatment Market, By Value (2012-2016)
7.2. Europe Hepatitis B Treatment Market, By Value (2017-2022)
7.3. Europe Hepatitis B Treatment Market - By Type, By Value
7.3.1. Europe Hepatitis B Treatment Market, By Value, % (2016)
7.3.2. Europe Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
7.4. Europe Hepatitis B Treatment Market, By Type, By Value (2012-2022)
7.4.1. Therapeutics, By Value (2012-2022)
7.4.2. Vaccines, By Value (2012-2022)
7.5. Europe Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
7.5.1. Male, By Value (2012-2022)
7.5.2. Female, By Value (2012-2022)

7.6. Euope Hepatitis B Treatment Market: Country Analysis (U.K., Germany, France)
7.6.1. Europe Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
7.6.2. Europe Hepatitis B Treatment Market, Country Share, 2022 (% of Total)

7.7. U.K. Hepatitis B Treatment Market: Growth and Forecast
7.7.1. U.K. Hepatitis B Treatment Market, By Value (2012-2016)
7.7.2. U.K. Hepatitis B Treatment Market, By Value (2017-2022)
7.8. U.K. Hepatitis B Treatment Market - By Type, By Value
7.8.1. Therapeutics, By Value (2012-2022)
7.8.2. Vaccines, By Value (2012-2022)
7.9. U.K. Hepatitis B Treatment Market - By End-User, By Value
7.9.1. Male, By Value (2012-2022)
7.9.2. Female, By Value (2012-2022)

7.10. Germany Hepatitis B Treatment Market: Growth and Forecast
7.10.1. Germany Hepatitis B Treatment Market, By Value (2012-2016)
7.10.2. Germany Hepatitis B Treatment Market, By Value (2017-2022)
7.11. Germany Hepatitis B Treatment Market - By Type, By Value
7.11.1. Therapeutics, By Value (2012-2022)
7.11.2. Vaccines, By Value (2012-2022)
7.12. Germany Hepatitis B Treatment Market - By End-User, By Value
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)

7.13. France Hepatitis B Treatment Market: Growth and Forecast
7.13.1. France Hepatitis B Treatment Market, By Value (2012-2016)
7.13.2. France Hepatitis B Treatment Market, By Value (2017-2022)
7.14. France Hepatitis B Treatment Market - By Type, By Value
7.14.1. Therapeutics, By Value (2012-2022)
7.14.2. Vaccines, By Value (2012-2022)
7.15. France Hepatitis B Treatment Market - By End-User, By Value
7.15.1. Male, By Value (2012-2022)
7.15.2. Female, By Value (2012-2022)

8. Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast
8.1. Asia-Pacific Hepatitis B Treatment Market, By Value (2012-2016)
8.2. Asia-Pacific Hepatitis B Treatment Market, By Value (2017-2022)
8.3. Asia-Pacific Hepatitis B Treatment Market - By Type, By Value
8.3.1. Asia-Pacific Hepatitis B Treatment Market, By Value, % (2016)
8.3.2. Asia-Pacific Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
8.4. Asia-Pacific Hepatitis B Treatment Market, By Type, By Value (2012-2022)
8.4.1. Therapeutics, By Value (2012-2022)
8.4.2. Vaccines, By Value (2012-2022)
8.5. Asia-Pacific Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
8.5.1. Male, By Value (2012-2022)
8.5.2. Female, By Value (2012-2022)

8.6. Asia-Pacific Hepatitis B Treatment Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2022 (% of Total)

8.7. Japan Hepatitis B Treatment Market: Growth and Forecast
8.7.1. Japan Hepatitis B Treatment Market, By Value (2012-2016)
8.7.2. Japan Hepatitis B Treatment Market, By Value (2017-2022)
8.8. Japan Hepatitis B Treatment Market - By Type, By Value
8.8.1. Therapeutics, By Value (2012-2022)
8.8.2. Vaccines, By Value (2012-2022)
8.9. Japan Hepatitis B Treatment Market - By End-User, By Value
8.9.1. Male, By Value (2012-2022)
8.9.2. Female, By Value (2012-2022)

8.10. China Hepatitis B Treatment Market: Growth and Forecast
8.10.1. China Hepatitis B Treatment Market, By Value (2012-2016)
8.10.2. China Hepatitis B Treatment Market, By Value (2017-2022)
8.11. China Hepatitis B Treatment Market - By Type, By Value
8.11.1. Therapeutics, By Value (2012-2022)
8.11.2. Vaccines, By Value (2012-2022)
8.12. China Hepatitis B Treatment Market - By End-User, By Value
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)

8.13. India Hepatitis B Treatment Market: Growth and Forecast
8.13.1. India Hepatitis B Treatment Market, By Value (2012-2016)
8.13.2. India Hepatitis B Treatment Market, By Value (2017-2022)
8.14. India Hepatitis B Treatment Market - By Type, By Value
8.14.1. Therapeutics, By Value (2012-2022)
8.14.2. Vaccines, By Value (2012-2022)
8.15. India Hepatitis B Treatment Market - By End-User, By Value
8.15.1. Male, By Value (2012-2022)
8.15.2. Female, By Value (2012-2022)

9. ROW Hepatitis B Treatment Market: Growth and Forecast
9.1. ROW Hepatitis B Treatment Market, By Value (2012-2016)
9.2. ROW Hepatitis B Treatment Market, By Value (2017-2022)

10. Market Dynamics
10.1. Increasing prevalence of Liver diseases due to Hepatitis B
10.2. Increasing awareness about the Hepatitis B & HBV
10.3. Rising healthcare expenditure worldwide

11. Market Restraints

12. SWOT Analysis – Hepatitis B Treatment Market

13. Porter’s Five Forces Analysis

14. Policy and Regulations

15. Global Hepatitis B Drugs Pipeline

16. Global Hepatitis B Treatment Market - Competitive Landscape

17. Company Profiles
17.1. Merck and Co
17.2. Gilead Sciences
17.3. Novartis AG
17.4. GlaxoSmithKline, plc
17.5. F.Hoffmann- La Roche
17.6. Bristol-Myers Squibb
17.7. AbbVie Inc.

"List of Figures

Figure 1: Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million)
Figure 2: Number of patients with Hepatitis B Virus (HBsAg) infection by WHO region, 2015 (In Million)
Figure 3: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 4: Global Hepatitis B Treatment Market Size, By Value, 2017-2022 (USD Million)
Figure 5: Global Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 6: Global Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 7: Global Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 8: Global Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 9: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Figure 10: Global Sales of Viread, By Value, 2015-2016 (USD Million)
Figure 11: Global Hepatitis B Treatment Market Size, By Region, 2016 (%)
Figure 12: Global Hepatitis B Treatment Market Size, By Region, 2022 (%)
Figure 13: North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 14: North America GDP, 2012-2015 (USD Trillion)
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 16: Population aged 65 & above, 2012-2016 (% of total)
Figure 17: North America Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 18: North America Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 19: North America Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 20: North America Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 21: North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
Figure 22: North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
Figure 23: U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 24: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 25: Reported acute (new) cases of Hepatitis B Virus in U.S., (2012-2015)
Figure 26: Incidences rate of acute Hepatitis B in U.S., By sex (2012-2015)
Figure 27: Incidence of acute Hepatitis B in U.S., By age group, (2012-2015)
Figure 28: U.S. Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 29: U.S. Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 30: Market Share of HBV approved Drugs in U.S., 2016 (% Share)
Figure 31: Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 32: Canada Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 33: Canada Life Expectancy at birth rate (Years), 2012-2015
Figure 34: Prevalence of Hepatitis B in Canada, (Patients per 100,000 (2012-2016)
Figure 35: Number of Hepatitis B Patients, Canada, (2013-2016)
Figure 36: Prevalence of Hepatitis B among Male population, Canada, (Patients per 100,000) (2012-2016)
Figure 37: Prevalence of Hepatitis B among Female population, Canada, (Patients per 100,000) (2012-2016)
Figure 38: Canada Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 39: Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 40: Europe Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 41: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 42: European Union Life Expectancy at birth rate (Years), 2012-2015
Figure 43: Reported Hepatitis B Cases, Number & Rate per 100,000 populations, EU/EEA, 2012-2015
Figure 44: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Figure 45: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Figure 46: Europe Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 47: Europe Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 48: Europe Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 49: Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 50: Europe Hepatitis B Treatment, Country Share, 2016 (% of Total)
Figure 51: Europe Hepatitis B Treatment, Country Share, 2022 (% of Total)
Figure 52: U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 53: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 54: U.K. Life Expectancy at birth rate (Years), 2012-2015
Figure 55: U.K. Women Population, 2012-2016
Figure 56: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 57: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 58: Number of Hepatitis B Patients, (2013-2016)
Figure 59: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 60: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 61: U.K. Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 62: U.K. Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 63: Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 64: Germany Population 65 Years & Above (% of Total), 2012-2016
Figure 65: Germany Life Expectancy at birth rate (Years), 2012-2015
Figure 66: Germany Women Population, 2012-2016
Figure 67: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 68: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 69: Number of Hepatitis B Patients, (2013-2016)
Figure 70: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 71: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 72: Germany Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 73: Germany Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 74: France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 75: France Population 65 Years & Above (% of Total), 2012-2016
Figure 76: France Life Expectancy at birth rate (Years), 2012-2015
Figure 77: France Women Population, 2012-2016
Figure 78: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 79: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 80: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 81: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 82: France Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 83: France Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 84: Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 85: Mortality due to Viral Hepatitis in South-East Asia region, 2015
Figure 86: Asia-Pacific Hepatitis B Treatment Size, By Type, 2016 (%)
Figure 87: Asia-Pacific Hepatitis B Drug Market Size, By Type, 2022 (%)
Figure 88: Asia-pacific Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 89: Asia-Pacific Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 90: Asia-Pacific Hepatitis B Treatment, Country Share, 2016 (% of Total)
Figure 91: Asia-Pacific Hepatitis B Treatment, Country Share, 2022 (% of Total)
Figure 92: Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 93: Japan Population 65 Years & Above (% of Total), 2012-2016
Figure 94: Japan Life Expectancy at birth rate (Years), 2012-2015
Figure 95: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 96: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 97: Number of Hepatitis B Patients, 2013-2016)
Figure 98: Prevalence of Hepatitis B among Male population (Patients per 100,000 (2012-2016)
Figure 99: Prevalence of Hepatitis B among Female population (Patients per 100,000 (2012-2016)
Figure 100: Japan Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 101: Japan Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 102: China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 103: China Population 65 Years & Above (% of Total), 2012-2016
Figure 104: China Life Expectancy at birth rate (Years), 2012-2015
Figure 105: China Women Population, 2012-2016
Figure 106: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 107: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 108: Number of Hepatitis B Patients, 2013-2016)
Figure 109: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 110: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 111: China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 112: China Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 113: India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 114: India Population 65 Years & Above (% of Total), 2012-2016
Figure 115: India Life Expectancy at birth rate (Years), 2012-2015
Figure 116: India Women Population, 2012-2016
Figure 117: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 118: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 119: Number of Hepatitis B Patients, 2013-2016)
Figure 120: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 121: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 122: India Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 123: India Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 124: ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 125: Prevalence of Hepatitis B in Brazil (Patients per 100,000 (2012-2016)
Figure 126: Number of Hepatitis B Patients in Brazil, (2013-2016)
Figure 127: Prevalence of Hepatitis B among Male population, in Brazil (Patients per 100,000) (2012-2016)
Figure 128: Prevalence of Hepatitis B among Female population in Brazil (Patients per 100,000) (2012-2016)
Figure 129: Prevalence of Hepatitis B in South Africa (Patients per 100,000 (2012-2016)
Figure 130: Number of Hepatitis B Patients in South Africa, (2013-2016)
Figure 131: Prevalence of Hepatitis B among Male population, in South Africa (Patients per 100,000) (2012-2016)
Figure 132: Prevalence of Hepatitis B among Female population (Patients per 100,000), in South Africa (2012-2016)
Figure 133: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 134: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Figure 135: Global Sales of Viread, By, Region, By Value, 2015-2016 (USD Million)
Figure 136: Merck & Co., Net Sales, 2012-2016 (In million USD)
Figure 137: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Figure 138: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Figure 139: Merck & Co., Net Revenue, By Business Segment, % Share 2016
Figure 140: Gilead Sciences Annual Revenue, 2014-2016 (USD Million)
Figure 141: Gilead Sciences HBV Product Sales, 2014-2016 (USD Million)
Figure 142: Gilead Sciences Revenue by Geographical, 2016 (%)
Figure 143: Gilead Sciences Product Sales, 2016 (%)
Figure 144: Novartis Annual Revenue, 2014-2016 (USD Million)
Figure 145: Innovative Medicine Net Sales, By Business Unit 2016 (%)
Figure 146: Novartis Sales, By Region, 2016 (%)
Figure 147: Novartis Sales, By Segment 2016 (%)
Figure 148: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
Figure 149: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Figure 150: Glaxosmithkline Sales, By Region, 2016 (%)
Figure 151: Glaxosmithkline, Sales, By Segment 2016 (%)
Figure 152: F. Hoffmann-La Roche Ltd Annual Revenue, 2014-2016 (USD Million)
Figure 153: F. Hoffmann-La Roche Ltd Segmental Break Up, By Revenue, By Business Division, 2016 (%)
Figure 154: F. Hoffmann-La Roche Ltd Geographical Break Up, By Revenue, 2016 (%)
Figure 155: Bristol-Myers Squibb Company Annual Revenue, 2014-2016 (USD Million)
Figure 156: Bristol-Myers Squibb Company Segmental Break Up, By Revenue, By Products, 2016 (%)
Figure 157: Bristol-Myers Squibb Company Geographical Break Up, By Revenue, 2016 (%)
Figure 158: Baraclude (entecavir), Annual Revenue, 2014-2016 (USD Million)
Figure 159: Baraclude (entecavir), Segmental Break Up, By geographical segment, 2016 (%)
Figure 160: AbbVie Revenue, Segmental Break Up, 2016
Figure 161: AbbVie Revenue, Geographical Break Up, 2016

List of Tables

Table A: Causes of Hepatitis B
Table B: HBV Approved Therapies
Table C: Globally Approved HBV Monovalent Vaccines
Table D: Compounds in development for chronic Hepatitis B

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87

The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......

Global Esomeprazole Magnesium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......

Global Combination Therapy Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......

Global Axitinib Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68

The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......

Global Lyme Disease Vaccine Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70

The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......

Global Transdermal Absorption Patch Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......

Global Ketoprofen Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......

Global Methyl Salicylate Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82

The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......

Global Diclofenac Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs